Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
June 06 2017 - 4:05PM
-Clinical Abstract will provide full data set
from ZGN-1061 Phase 1 Clinical Trial-
Zafgen, Inc. (Nasdaq:ZFGN) today announced two late-breaking
abstracts were accepted for poster presentations at the upcoming
American Diabetes Association 77th Scientific Sessions being held
in San Diego from June 9-13, 2017. The clinical abstract titled,
“Single and Multiple Dose Evaluation of a Novel MetAP2 Inhibitor:
Results of a Randomized, Double-Blind, Placebo-Controlled Clinical
Trial,” will include the full data set from the Phase 1 clinical
trial of ZGN-1061, the Company’s second generation MetAP2
inhibitor. The Company will also present a preclinical abstract
titled, “The MetAP2 Inhibitor ZGN-1061 Improves Glycemia and Has
Weight Loss Efficacy with an Improved Safety Profile in Preclinical
Models.”
Poster Presentations:Poster Number: 144-LBTitle:
Single and Multiple Dose Evaluation of a Novel MetAP2 Inhibitor:
Results of a Randomized, Double-Blind, Placebo-Controlled Clinical
TrialCategory: 12-D Clinical Therapeutics/New
Technology–Non-Insulin InjectablesLate-Breaking Poster Session:
Sunday, June 11, 2017, 12-1pm PDT
Poster Number: 143-LBTitle: The MetAP2 Inhibitor
ZGN-1061 Improves Glycemia and Has Weight Loss Efficacy with an
Improved Safety Profile in Preclinical ModelsCategory: 12-D
Clinical Therapeutics/New Technology–Non-Insulin
InjectablesLate-Breaking Poster Session: Sunday, June 11,
2017, 12-1pm PDT
About ZGN-1061
ZGN-1061 is a fumagillin-class, injectable small
molecule second generation MetAP2 inhibitor that was advanced into
development due to its unique properties that maximize impact on
metabolic parameters relevant to the treatment of type 2 diabetes
and other related metabolic disorders. In pre-clinical studies,
ZGN-1061 has demonstrated promising efficacy in animal models of
type 2 diabetes and obesity, with an improved pharmacokinetic
profile and safety margin relative to previous molecules in the
MetAP2 class. As demonstrated clinically for MetAP2 inhibitors,
ZGN-1061 is anticipated to improve glycemic control while also
helping to restore balance to fat metabolism, enabling calories to
once again be used as a productive energy source, leading to
improved metabolic control and long-term weight loss. Zafgen
recently completed its first Phase 1 clinical trial of ZGN-1061,
and is planning to advance the compound to Phase 2 clinical testing
in patients with type 2 diabetes who are overweight or
obese. Zafgen holds exclusive worldwide rights for the
development and commercialization of ZGN-1061.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical
company dedicated to significantly improving the health and
well-being of patients affected by metabolic diseases including
type 2 diabetes and obesity. Zafgen is focused on developing novel
therapeutics that treat the underlying biological mechanisms of
metabolic diseases through the MetAP2 pathway. Zafgen has pioneered
the study of MetAP2 inhibitors in both common and rare forms of
obesity, and in patients affected by type 2 diabetes. Zafgen's lead
product candidate is ZGN-1061, which is a novel, first-in-class,
subcutaneous injection. Zafgen aspires to improve the lives of
patients through targeted treatments and has assembled a team
accomplished in bringing therapies to patients affected by
metabolic diseases.
Safe Harbor Statement
Various statements in this release concerning
Zafgen's future expectations, plans and prospects, including
without limitation, Zafgen's expectations regarding the use of
ZGN-1061 and other MetAP2 inhibitors as treatments for metabolic
diseases including type 2 diabetes and obesity, ZGN-1061’s improved
safety margin, including as it relates to pro-thrombotic
characteristics, compared to first generation MetAP2 inhibitors,
such as over beloranib, and Zafgen's expectations with respect to
the timing and success of its pre-clinical studies and clinical
trials of ZGN-1061 and its other product candidates, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995 and other federal securities laws. Forward-looking statements
can be identified by terminology such as "anticipate," "believe,"
"could," "could increase the likelihood," "estimate," "expect,"
"intend," "is planned," "may," "should," "will," "will enable,"
"would be expected," "look forward," "may provide," "would" or
similar terms, variations of such terms or the negative of those
terms. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, Zafgen's ability to
successfully demonstrate the efficacy and safety of ZGN-1061 and
its other product candidates and to differentiate ZGN-1061 and its
other product candidates from first generation MetAP2 inhibitors,
such as beloranib, the pre-clinical and clinical results for
ZGN-1061 and its other product candidates, which may not support
further development and marketing approval, actions of regulatory
agencies, which may affect the initiation, timing and progress of
pre-clinical studies and clinical trials of its product candidates,
Zafgen's ability to obtain, maintain and protect its intellectual
property, Zafgen's ability to enforce its patents against
infringers and defend its patent portfolio against challenges from
third parties, competition from others developing products for
similar uses, Zafgen's ability to manage operating expenses,
Zafgen's ability to obtain additional funding to support its
business activities and establish and maintain strategic business
alliances and new business initiatives when needed, Zafgen's
dependence on third parties for development, manufacture,
marketing, sales and distribution of product candidates, the
outcome of litigation, and unexpected expenditures, as well as
those risks more fully discussed in the section entitled "Risk
Factors" in Zafgen's most recent Annual Report on Form 10-K filed
with the Securities and Exchange Commission, as well as discussions
of potential risks, uncertainties, and other important factors in
Zafgen's subsequent filings with the Securities and Exchange
Commission. In addition, any forward-looking statements represent
Zafgen's views only as of today and should not be relied upon as
representing its views as of any subsequent date. Zafgen explicitly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media/Investor Relations Contact:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Argot Partners
Investor Relations
Laura Perry
212-600-1902
laura@argotpartners.com
Spectrum Science
Media Relations
Michelle Strier
202-587-2582
mstrier@spectrumscience.com
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2024 to May 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From May 2023 to May 2024